Lian-Wang Guo | Genetics and Molecular Biology| Best Researcher Award Posted on 16/10/202418/10/2024 by ScienceFather Dr. Lian-Wang Guo | Genetics and Molecular Biology| Best Researcher Award Professor at University of Virginia, United States Dr. Lian-Wang Guo is a Professor of Biomedical Sciences at the University of Virginia with over 20 years of experience in vascular biology and biochemistry. His research primarily focuses on the role of epigenetic modulators in vascular diseases, particularly neointima-associated restenosis. He has been continuously funded by the NIH since 2012 and has published 48 peer-reviewed papers in the past six years, while also filing six patent applications. Dr. Guo’s innovative work includes developing biomimetic nanoplatforms for targeted drug delivery, which are currently in advanced trials for treating vascular conditions. His research integrates basic science with clinical applications, notably through collaboration with Dr. Craig Kent. Dr. Guo is recognized for his significant contributions to vascular epigenetics and has created a rigorous and inclusive training environment for young researchers. His work holds promise for advancing therapeutic strategies and improving clinical outcomes for vascular diseases. Professional Profile Scopus Profile ORCID Google Scholar Education Dr. Lian-Wang Guo’s educational background is rooted in biology and advanced plant physiology, providing a strong foundation for his extensive research career. He earned his Bachelor of Science degree in Biology from Xinjiang University in China in 1989, followed by a Master of Science in Plant Physiology from the prestigious Chinese Academy of Sciences in 1992. He continued his studies there, earning a Ph.D. in Plant Physiology and Biochemistry in 1995. Driven by a passion for genetics and biochemistry, Dr. Guo completed a postdoctoral fellowship at The Hebrew University of Jerusalem in 1998, where he broadened his research expertise in molecular biology. His educational journey reflects a commitment to understanding complex biological processes, which he has successfully applied to his pioneering work in vascular biology and epigenetics. Dr. Guo’s solid academic training has been instrumental in his innovative research contributions and leadership in biomedical sciences. Professional Experience Dr. Lian-Wang Guo is a tenured Professor of Biomedical Sciences at the University of Virginia, specializing in vascular biology and epigenetics. With over 20 years of research experience, Dr. Guo has developed an expertise in chromatin modulators and their role in vascular diseases, particularly in neointima-associated restenosis. He has been continuously funded by the NIH since 2012, and his prolific contributions include 48 peer-reviewed publications and multiple patents, reflecting his leadership in vascular epigenetics research. His laboratory employs advanced molecular techniques such as ChIPseq, RNAseq, bioinformatics, and innovative nanoplatforms for targeted drug delivery. Dr. Guo has also successfully fostered clinical collaborations, including the development of therapeutic interventions currently undergoing large animal trials, with preparations for human studies. A dedicated mentor, he has cultivated a rigorous training environment for students and fellows, helping them transition into independent research careers. His research has garnered numerous awards and recognition from prominent scientific organizations. Research Interests Lian-Wang Guo’s research interests center around the intersection of vascular biology, epigenetics, and targeted drug delivery. As a professor of Biomedical Sciences, his work focuses on understanding the role of chromatin modulators, such as EZH2, DOT1L, and BRD4, in vascular diseases, particularly neointima-associated restenosis. By uncovering how these epigenetic regulators influence disease-specific gene expression, he aims to develop precise therapeutic strategies that mitigate pathological vascular remodeling while preserving normal cellular functions. Dr. Guo is also deeply involved in translational research, advancing the use of biomimetic nanoplatforms for targeted, localized drug delivery. His lab has developed innovative nanotechnologies to deliver therapeutic agents to disease sites, aiming to enhance efficacy and minimize side effects. A key element of his research is the integration of basic science discoveries with clinical applications, as evidenced by his collaborations on vascular disease treatments currently in advanced stages of preclinical testing. Awards and Honors Lian-Wang Guo, Professor of Biomedical Sciences at the University of Virginia, has earned numerous prestigious awards and honors throughout his distinguished career. In 1996, he received the Award of Excellent Sci/Tech Articles from the Chinese Society of Plant Physiology. He has also been recognized with the University of Wisconsin-Madison Eye Research Institute Rapid Response Initiative Award (2008), the Morgridge Institute for Research Award (2014), and the New Investigator Award from the State of Wisconsin Partnership Program (2014). At The Ohio State University, he earned the Accelerator Award for Translation (2017). His editorial contributions include serving as Lead Guest Editor for Genes and Associate Editor for Frontiers in Cardiovascular Medicine. In 2023, he was elected as a Fellow of the American Heart Association (FAHA), and his outstanding research earned him recognition at the 2023 Research Achievement event at the University of Virginia, marking him as a leading figure in vascular biology and biomedical research. Conclusion Dr. Lian-Wang Guo’s extensive research contributions, particularly in vascular biology and epigenetics, position him as a leading scholar in biomedical sciences. His innovative work on chromatin modulators, specifically targeting epigenetic players like BRD4, EZH2, and DOT1L, has brought new insights into the treatment of neointimal-associated vascular diseases. Additionally, his development of nano-based, targeted drug delivery systems has shown promising translational potential, bridging the gap between basic science and clinical applications. With over 20 years of experience, numerous high-impact publications, NIH funding, and significant patents, Dr. Guo’s work is both cutting-edge and impactful. His mentorship of the next generation of scientists, as well as his collaborations with leading clinicians, further enhance his academic profile. While his contributions are already significant, a continued focus on clinical translation could maximize the impact of his research. Overall, Dr. Guo exemplifies the qualities of an outstanding researcher deserving of recognition. Publication top noted Article: Transmembrane protein TMEM97 and epigenetic reader BAHCC1 constitute an axis that supports pro-inflammatory cytokine expression Authors: Li, J., Shen, H., Guo, L.-W. Year: 2024 Citations: 0 Article: miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4 Authors: Xie, X., Shirasu, T., Li, J., Guo, L.-W., Kent, K.C. Year: 2023 Citations: 3 Article: Neointima abating and endothelium preserving — An adventitia-localized nanoformulation to inhibit the epigenetic writer DOT1L Authors: Shirasu, T., Yodsanit, N., Li, J., Gong, S., Guo, L.-W. Year: 2023 Citations: 1 Article: Targeted PERK inhibition with biomimetic nanoclusters confers preventative and interventional benefits to elastase-induced abdominal aortic aneurysms Authors: Yodsanit, N., Shirasu, T., Huang, Y., Gong, S., Wang, B. Year: 2023 Citations: 2 Article: Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation Authors: Zhang, M., Li, J., Wang, Q., Miller, C.L., Guo, L.-W. Year: 2023 Citations: 3 Article: Sphingoid Bases Regulate the Sigma-1 Receptor—Sphingosine and N,N’-Dimethylsphingosine Are Endogenous Agonists Authors: Li, J., Satyshur, K.A., Guo, L.-W., Ruoho, A.E. Year: 2023 Citations: 3 Article: Retinal Photoreceptor Protection in an AMD-Related Mouse Model by Selective Sigma-1 or Sigma-2 Receptor Modulation Authors: Mavlyutov, T.A., Li, J., Liu, X., Pattnaik, B., Guo, L.-W. Year: 2022 Citations: 4 Erratum: Correction: miR548ai antagonism attenuates exosome-induced endothelial cell dysfunction (Cell Death Discovery, (2021), 7, 1, (318), 10.1038/s41420-021-00720-9) Authors: Xie, X., Guo, L.-W., Kent, C.K. Year: 2022 Citations: 0 Article: Differential Responses to Sigma-1 or Sigma-2 Receptor Ablation in Adiposity, Fat Oxidation, and Sexual Dimorphism Authors: Li, J., Félix-Soriano, E., Wright, K.R., Stanford, K.I., Guo, L.-W. Year: 2022 Citations: 5 Article: SREBP1 regulates Lgals3 activation in response to cholesterol loading Authors: Li, J., Shen, H., Owens, G.K., Guo, L.-W. Year: 2022 Citations: 9
Dr. Lian-Wang Guo is a Professor of Biomedical Sciences at the University of Virginia with over 20 years of experience in vascular biology and biochemistry. His research primarily focuses on the role of epigenetic modulators in vascular diseases, particularly neointima-associated restenosis. He has been continuously funded by the NIH since 2012 and has published 48 peer-reviewed papers in the past six years, while also filing six patent applications. Dr. Guo’s innovative work includes developing biomimetic nanoplatforms for targeted drug delivery, which are currently in advanced trials for treating vascular conditions. His research integrates basic science with clinical applications, notably through collaboration with Dr. Craig Kent. Dr. Guo is recognized for his significant contributions to vascular epigenetics and has created a rigorous and inclusive training environment for young researchers. His work holds promise for advancing therapeutic strategies and improving clinical outcomes for vascular diseases.
Lian-Wang Guo’s research interests center around the intersection of vascular biology, epigenetics, and targeted drug delivery. As a professor of Biomedical Sciences, his work focuses on understanding the role of chromatin modulators, such as EZH2, DOT1L, and BRD4, in vascular diseases, particularly neointima-associated restenosis. By uncovering how these epigenetic regulators influence disease-specific gene expression, he aims to develop precise therapeutic strategies that mitigate pathological vascular remodeling while preserving normal cellular functions. Dr. Guo is also deeply involved in translational research, advancing the use of biomimetic nanoplatforms for targeted, localized drug delivery. His lab has developed innovative nanotechnologies to deliver therapeutic agents to disease sites, aiming to enhance efficacy and minimize side effects. A key element of his research is the integration of basic science discoveries with clinical applications, as evidenced by his collaborations on vascular disease treatments currently in advanced stages of preclinical testing.
Lian-Wang Guo, Professor of Biomedical Sciences at the University of Virginia, has earned numerous prestigious awards and honors throughout his distinguished career. In 1996, he received the Award of Excellent Sci/Tech Articles from the Chinese Society of Plant Physiology. He has also been recognized with the University of Wisconsin-Madison Eye Research Institute Rapid Response Initiative Award (2008), the Morgridge Institute for Research Award (2014), and the New Investigator Award from the State of Wisconsin Partnership Program (2014). At The Ohio State University, he earned the Accelerator Award for Translation (2017). His editorial contributions include serving as Lead Guest Editor for Genes and Associate Editor for Frontiers in Cardiovascular Medicine. In 2023, he was elected as a Fellow of the American Heart Association (FAHA), and his outstanding research earned him recognition at the 2023 Research Achievement event at the University of Virginia, marking him as a leading figure in vascular biology and biomedical research.
Elham Nazari | Biology and Genetics | Best Researcher Award Posted on 13/09/2024 by ScienceFather Assist Prof Dr. Elham Nazari | Biology and Genetics | Best Researcher Award Shahid beheshti university of medical science, Iran Dr. Elham Nazari is a prominent researcher in bioinformatics and medical informatics, with a strong academic background including a Ph.D. and Postdoc from Mashhad University of Medical Sciences. Her research focuses on integrating machine learning, big data analysis, and multi-omics approaches to identify biomarkers and prognostic indicators in various cancers, including colorectal, gastric, and pancreatic. Dr. Nazari has published extensively in reputable journals such as Current Bioinformatics and Scientific Reports, showcasing her expertise in applying advanced computational methods to healthcare problems. Her work also includes contributions to understanding the impact of big data and digital innovation on healthcare systems. Dr. Nazari’s research has been supported by multiple grants, and she has been recognized for her scholarly achievements, including awards for her research and presentations. Her skills in using tools like SPSS, R, and Python underscore her proficiency in handling complex data analyses. Profile Google Scholar Profile Scopus Profile Education Elham Nazari’s educational background reflects a robust foundation in bioinformatics and medical informatics. She earned her Bachelor of Science in Computer Engineering from Azad University of Kermanshah in 2006. Building on this foundation, she pursued a Master of Science in Medical Informatics at Tarbiat Modares University of Tehran, completing her degree in 2015. Her academic journey continued with a PhD in Medical Informatics from Mashhad University of Medical Sciences, which she obtained in 2021. Her research interests and expertise were further expanded through a Postdoctoral Fellowship in Bioinformatics at Mashhad University of Medical Sciences, which she completed in 2023. This extensive educational experience underpins her significant contributions to the field of bioinformatics and her proficiency in integrating machine learning and big data analysis in medical research. Professional Experience Elham Nazari is an accomplished researcher with a solid foundation in medical informatics and bioinformatics. She completed her postdoctoral training in Bioinformatics at Mashhad University of Medical Sciences in 2023, following a PhD in Medical Informatics from the same institution in 2021. Prior to her doctoral studies, she earned a Master’s degree in Medical Informatics from Tarbiat Modares University in Tehran (2015) and a Bachelor’s in Computer Engineering from Azad University of Kermanshah (2006). Her professional experience includes extensive research in machine learning, big data analysis, and bioinformatics, with notable projects focusing on cancer biomarker identification and predictive modeling. Nazari’s work has been supported by multiple research grants and has resulted in numerous peer-reviewed publications and conference presentations. Additionally, she has taught technical courses in visual basic and software applications at various institutions. Her diverse expertise and research contributions highlight her significant impact in the field of medical informatics. Research Interest Elham Nazari’s research interests are centered on the integration of bioinformatics and machine learning to advance medical and healthcare outcomes. Her work predominantly focuses on utilizing machine learning algorithms for identifying biomarkers and understanding the molecular mechanisms underlying various cancers, including gastric, colorectal, and pancreatic cancers. She is deeply involved in data science and big data analysis, leveraging these tools to enhance RNA and DNA sequencing techniques. Additionally, Nazari’s research extends to multi-omics analysis, where she applies computational methods to integrate and analyze complex biological data. Her expertise encompasses bioinformatics, with a particular emphasis on developing predictive models and discovering novel diagnostic and prognostic markers. By combining her skills in bioinformatics with cutting-edge machine learning techniques, Nazari aims to improve early detection and treatment strategies for cancer and other diseases. Research Skills Elham Nazari possesses a robust set of research skills that significantly contribute to her field of bioinformatics and medical informatics. Her expertise in machine learning and data science is evident through her extensive work in developing predictive models and identifying biomarkers using advanced computational techniques. Nazari’s proficiency in big data analysis allows her to handle and interpret large datasets, which is crucial for her research in RNA and DNA sequencing. Her skill set includes using bioinformatics tools for multi-omics analysis, enhancing her ability to uncover complex patterns and relationships in biological data. She is adept with a range of software such as SPSS, R, Python, and Weka, facilitating her analysis and modeling tasks. Her research experience spans various applications, including cancer biomarker identification and health data analytics, showcasing her versatility and depth in the domain. Award and Recognition Elham Nazari has garnered significant recognition for her contributions to the field of medical informatics and bioinformatics. Notably, she was honored as a selective and excellent student and researcher at the Festival Professor Hesabi in 2019, highlighting her outstanding achievements and academic prowess. Additionally, she received the Best Poster Award at the Second National Conference of Medical Informatics in 2018, underscoring her excellence in presenting innovative research. Nazari’s work is widely acknowledged in the academic community, as reflected in her extensive publication record and active participation in cutting-edge research projects. Her innovative use of machine learning and big data analysis in healthcare continues to earn accolades, reflecting her dedication and impact in advancing the field. Her contributions are further supported by a strong online presence and recognition from peers, showcasing her prominent role in advancing medical informatics and bioinformatics. Conclusion Elham Nazari is a strong candidate for the Research for Best Researcher Award due to her extensive research output, innovative use of technology, and active engagement in impactful projects. Her expertise in bioinformatics and machine learning, coupled with her robust academic background, positions her as a leading figure in her field. Addressing areas for improvement, such as increasing public engagement and expanding research focus, could further enhance her already impressive profile. Publications Top Notes The Therapeutic Impact of Programmed Death–1 in the Treatment of Colorectal Cancer Authors: P.S. Sangani, S. Yazdani, G. Khalili-Tanha, E. Nazari, A. Avan Year: 2024 Journal: Pathology Research and Practice Emerging Potential Value of Long Non-Coding RNAs as Biomarkers and Therapeutic Targets in Pancreatic Cancer Authors: Z. Haghshenas, F. Shaban, G.A. Ferns, E. Nazari Year: 2024 Journal: Annals of Pancreatic Cancer The Prognostic, Diagnostic, and Therapeutic Impact of Long Noncoding RNAs in Gastric Cancer Authors: A. Ghorbani, F. Hosseinie, S. Khorshid Sokhangouy, E. Nazari, A. Avan Year: 2024 Journal: Cancer Genetics Colorectal Cancer Stem Cell Biomarkers: Biological Traits and Prognostic Insights Authors: A. Soleimani, N. Saeedi, A.M. Al-Asady, A. Avan, S.M.H. Mehr Year: 2024 Journal: Current Pharmaceutical Design Citations: 1 The Therapeutic Application of Hydrogen in Cancer: The Potential and Challenges Authors: M.N. Khiji, F. Arghidash, G.K. Tanha, E. Nazari, A. Avan Year: 2024 Journal: Current Pharmaceutical Design Citations: 1 Bioinformatics Analysis and Machine Learning Approach Applied to the Identification of Novel Key Genes Involved in Non-Alcoholic Fatty Liver Disease Authors: E. Nazari, G. Khalili-Tanha, A. Asadnia, M.A. Kiani, A. Avan Year: 2023 Journal: Scientific Reports Citations: 1 Down Regulation of Cathepsin W is Associated with Poor Prognosis in Pancreatic Cancer Authors: F. Khojasteh-Leylakoohi, R. Mohit, N. Khalili-Tanha, J. Batra, A. Avan Year: 2023 Journal: Scientific Reports Citations: 4 Breast Cancer Prediction Using Different Machine Learning Methods Applying Multi Factors Authors: E. Nazari, H. Naderi, M. Tabadkani, H. Tabesh, A. Avan Year: 2023 Journal: Journal of Cancer Research and Clinical Oncology Citations: 3 Identification of ZMYND19 as a Novel Biomarker of Colorectal Cancer: RNA-Sequencing and Machine Learning Analysis Authors: G. Khalili-Tanha, R. Mohit, A. Asadnia, E. Nazari, A. Avan Year: 2023 Journal: Journal of Cell Communication and Signaling Citations: 2 Prognostic Value of Primary Tumor Location in Colorectal Cancer: An Updated Meta-Analysis Authors: H. Gholamalizadeh, N. Zafari, M. Velayati, E. Nazari, A. Avan Year: 2023 Journal: Clinical and Experimental Medicine Citations: 2
Dr. Elham Nazari is a prominent researcher in bioinformatics and medical informatics, with a strong academic background including a Ph.D. and Postdoc from Mashhad University of Medical Sciences. Her research focuses on integrating machine learning, big data analysis, and multi-omics approaches to identify biomarkers and prognostic indicators in various cancers, including colorectal, gastric, and pancreatic. Dr. Nazari has published extensively in reputable journals such as Current Bioinformatics and Scientific Reports, showcasing her expertise in applying advanced computational methods to healthcare problems. Her work also includes contributions to understanding the impact of big data and digital innovation on healthcare systems. Dr. Nazari’s research has been supported by multiple grants, and she has been recognized for her scholarly achievements, including awards for her research and presentations. Her skills in using tools like SPSS, R, and Python underscore her proficiency in handling complex data analyses. Profile Google Scholar Profile Scopus Profile Education Elham Nazari’s educational background reflects a robust foundation in bioinformatics and medical informatics. She earned her Bachelor of Science in Computer Engineering from Azad University of Kermanshah in 2006. Building on this foundation, she pursued a Master of Science in Medical Informatics at Tarbiat Modares University of Tehran, completing her degree in 2015. Her academic journey continued with a PhD in Medical Informatics from Mashhad University of Medical Sciences, which she obtained in 2021. Her research interests and expertise were further expanded through a Postdoctoral Fellowship in Bioinformatics at Mashhad University of Medical Sciences, which she completed in 2023. This extensive educational experience underpins her significant contributions to the field of bioinformatics and her proficiency in integrating machine learning and big data analysis in medical research. Professional Experience Elham Nazari is an accomplished researcher with a solid foundation in medical informatics and bioinformatics. She completed her postdoctoral training in Bioinformatics at Mashhad University of Medical Sciences in 2023, following a PhD in Medical Informatics from the same institution in 2021. Prior to her doctoral studies, she earned a Master’s degree in Medical Informatics from Tarbiat Modares University in Tehran (2015) and a Bachelor’s in Computer Engineering from Azad University of Kermanshah (2006). Her professional experience includes extensive research in machine learning, big data analysis, and bioinformatics, with notable projects focusing on cancer biomarker identification and predictive modeling. Nazari’s work has been supported by multiple research grants and has resulted in numerous peer-reviewed publications and conference presentations. Additionally, she has taught technical courses in visual basic and software applications at various institutions. Her diverse expertise and research contributions highlight her significant impact in the field of medical informatics. Research Interest Elham Nazari’s research interests are centered on the integration of bioinformatics and machine learning to advance medical and healthcare outcomes. Her work predominantly focuses on utilizing machine learning algorithms for identifying biomarkers and understanding the molecular mechanisms underlying various cancers, including gastric, colorectal, and pancreatic cancers. She is deeply involved in data science and big data analysis, leveraging these tools to enhance RNA and DNA sequencing techniques. Additionally, Nazari’s research extends to multi-omics analysis, where she applies computational methods to integrate and analyze complex biological data. Her expertise encompasses bioinformatics, with a particular emphasis on developing predictive models and discovering novel diagnostic and prognostic markers. By combining her skills in bioinformatics with cutting-edge machine learning techniques, Nazari aims to improve early detection and treatment strategies for cancer and other diseases. Research Skills Elham Nazari possesses a robust set of research skills that significantly contribute to her field of bioinformatics and medical informatics. Her expertise in machine learning and data science is evident through her extensive work in developing predictive models and identifying biomarkers using advanced computational techniques. Nazari’s proficiency in big data analysis allows her to handle and interpret large datasets, which is crucial for her research in RNA and DNA sequencing. Her skill set includes using bioinformatics tools for multi-omics analysis, enhancing her ability to uncover complex patterns and relationships in biological data. She is adept with a range of software such as SPSS, R, Python, and Weka, facilitating her analysis and modeling tasks. Her research experience spans various applications, including cancer biomarker identification and health data analytics, showcasing her versatility and depth in the domain. Award and Recognition Elham Nazari has garnered significant recognition for her contributions to the field of medical informatics and bioinformatics. Notably, she was honored as a selective and excellent student and researcher at the Festival Professor Hesabi in 2019, highlighting her outstanding achievements and academic prowess. Additionally, she received the Best Poster Award at the Second National Conference of Medical Informatics in 2018, underscoring her excellence in presenting innovative research. Nazari’s work is widely acknowledged in the academic community, as reflected in her extensive publication record and active participation in cutting-edge research projects. Her innovative use of machine learning and big data analysis in healthcare continues to earn accolades, reflecting her dedication and impact in advancing the field. Her contributions are further supported by a strong online presence and recognition from peers, showcasing her prominent role in advancing medical informatics and bioinformatics. Conclusion Elham Nazari is a strong candidate for the Research for Best Researcher Award due to her extensive research output, innovative use of technology, and active engagement in impactful projects. Her expertise in bioinformatics and machine learning, coupled with her robust academic background, positions her as a leading figure in her field. Addressing areas for improvement, such as increasing public engagement and expanding research focus, could further enhance her already impressive profile. Publications Top Notes The Therapeutic Impact of Programmed Death–1 in the Treatment of Colorectal Cancer Authors: P.S. Sangani, S. Yazdani, G. Khalili-Tanha, E. Nazari, A. Avan Year: 2024 Journal: Pathology Research and Practice Emerging Potential Value of Long Non-Coding RNAs as Biomarkers and Therapeutic Targets in Pancreatic Cancer Authors: Z. Haghshenas, F. Shaban, G.A. Ferns, E. Nazari Year: 2024 Journal: Annals of Pancreatic Cancer The Prognostic, Diagnostic, and Therapeutic Impact of Long Noncoding RNAs in Gastric Cancer Authors: A. Ghorbani, F. Hosseinie, S. Khorshid Sokhangouy, E. Nazari, A. Avan Year: 2024 Journal: Cancer Genetics Colorectal Cancer Stem Cell Biomarkers: Biological Traits and Prognostic Insights Authors: A. Soleimani, N. Saeedi, A.M. Al-Asady, A. Avan, S.M.H. Mehr Year: 2024 Journal: Current Pharmaceutical Design Citations: 1 The Therapeutic Application of Hydrogen in Cancer: The Potential and Challenges Authors: M.N. Khiji, F. Arghidash, G.K. Tanha, E. Nazari, A. Avan Year: 2024 Journal: Current Pharmaceutical Design Citations: 1 Bioinformatics Analysis and Machine Learning Approach Applied to the Identification of Novel Key Genes Involved in Non-Alcoholic Fatty Liver Disease Authors: E. Nazari, G. Khalili-Tanha, A. Asadnia, M.A. Kiani, A. Avan Year: 2023 Journal: Scientific Reports Citations: 1 Down Regulation of Cathepsin W is Associated with Poor Prognosis in Pancreatic Cancer Authors: F. Khojasteh-Leylakoohi, R. Mohit, N. Khalili-Tanha, J. Batra, A. Avan Year: 2023 Journal: Scientific Reports Citations: 4 Breast Cancer Prediction Using Different Machine Learning Methods Applying Multi Factors Authors: E. Nazari, H. Naderi, M. Tabadkani, H. Tabesh, A. Avan Year: 2023 Journal: Journal of Cancer Research and Clinical Oncology Citations: 3 Identification of ZMYND19 as a Novel Biomarker of Colorectal Cancer: RNA-Sequencing and Machine Learning Analysis Authors: G. Khalili-Tanha, R. Mohit, A. Asadnia, E. Nazari, A. Avan Year: 2023 Journal: Journal of Cell Communication and Signaling Citations: 2 Prognostic Value of Primary Tumor Location in Colorectal Cancer: An Updated Meta-Analysis Authors: H. Gholamalizadeh, N. Zafari, M. Velayati, E. Nazari, A. Avan Year: 2023 Journal: Clinical and Experimental Medicine Citations: 2